PracticeUpdate Oncology February 2019

CONTENTS 3

EXPERT OPINION 18 Brain Metastases: A Brave New World By Rupesh R. Kotecha MD COVER 6 Ibrutinib Regimens vs Chemoimmunotherapy in Older Patients With Untreated CLL Comments by Isabel Cunningham MD and Alessandra Ferrajoli MD

RESEARCH Editor’s picks 6 Ibrutinib Regimens vs

Chemoimmunotherapy in Older Patients With Untreated CLL Comments by Isabel Cunningham MD and Alessandra Ferrajoli MD 7 Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade 8 Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous mRCC Receiving Sunitinib Comment by Sumanta Kumar Pal MD 9 FOLFIRINOX Adjuvant Therapy Increases

20 Combination of Immune Checkpoint Blockade and Tumor Vaccine for HPV+ Cancer Interview with Barbara Burtness MD by Tyeese L. Gaines DO 21 First- vs Next-Generation TKIs for NSCLC With Driver Mutations Interview with Benjamin Besse MD by Tyeese L. Gaines DO Interview with Lee S. Schwartzberg MD, FACP by Farzanna S. Haffizulla MD, FACP, FAMWA 24 Baseline Circulating ESR1 Mutation Analysis From the EFECT study Interview with William John Gradishar MD, FACP by Farzanna S. Haffizulla MD, FACP, FAMWA 26 Neoadjuvant Talazoparib for BRCA 1/2 Mutated Triple-Negative Breast Cancer Interview with Jennifer Litton MD by Farzanna S. Haffizulla MD, FACP, FAMWA 27 Regional Analysis of Talazoparib for Treatment of Advanced Breast Cancer With Germline BRCA 1/2 Mutation Interview with Jennifer Litton MD by Farzanna S. Haffizulla MD, FACP, FAMWA 28 Race, Ethnicity, and Clinical Outcomes From the TAILORx Trial Interview with Sunil S. Badve MD, FRCPath by Farzanna S. Haffizulla MD, FACP, FAMWA 30 Lasofoxifene vs Fulvestrant for HR-Positive Breast Cancer Interview with Lee S. Schwartzberg MD, FACP by Farzanna S. Haffizulla MD, FACP, FAMWA 24 Eflapegrastim for Reducing Severe Neutropenia

Survival in Pancreatic Cancer Comment by Axel Grothey MD

CONFERENCE 22 San Antonio Breast Cancer Symposium 2018

10 Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Comment by Lee S. Schwartzberg MD, FACP 11 Assessment of a Watch-and-Wait Strategy for Rectal Cancer Following Complete Response After Neoadjuvant Therapy Comment by Axel Grothey MD 12 Men With Clinically Detected, Localized Prostate Cancer Benefit From Radical Prostatectomy Comment by H. Ballentine Carter MD 13 Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer Comment by Lee S. Schwartzberg MD, FACP 14 Venetoclax Plus Decitabine or Azacitidine in Treatment-Naive, Elderly Patients With AML Comment by Isabel Cunningham MD 15 Underdiagnosis of Hereditary Breast Cancer Comment by Lee S. Schwartzberg MD, FACP 16 Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease 17 Association of Gender With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers Comment by Sumanta Kumar Pal MD

22 Adjuvant T-DM1 for HER2+ Breast Cancer: Critical Data From The KATHERINE Study Interview with Jame Abraham MD, FACP by Farzanna S. Haffizulla MD, FACP, FAMWA 23 Subgroup Analysis of Combination Immunotherapy for Triple-Negative Breast Cancer Interview with Alison K. Conlin MD by Farzanna S. Haffizulla MD, FACP, FAMWA

VOL. 3 • NO. 1 • 2019